Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc (CNTA) Financial Performance & Income Statement Overview
Explore the financials of Centessa Pharmaceuticals plc (CNTA), including yearly and quarterly data on income, cash flow, and balance sheets.
Centessa Pharmaceuticals plc (CNTA) Income Statement & Financial Overview
Review Centessa Pharmaceuticals plc CNTA income statement with detailed quarterly and annual figures.
| Metric | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $6.91M |
| Cost of Revenue | $0.00 | $236264.00 | $239862.00 | $248139.00 |
| Gross Profit | $0.00 | -$236264.00 | -$239862.00 | $6.66M |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.96 |
| R&D Expenses | $33.90M | $32.81M | $22.64M | $29.97M |
| SG&A Expenses | $12.50M | $11.16M | $13.19M | $12.17M |
| Operating Expenses | $46.41M | $43.98M | $35.83M | $42.15M |
| Total Costs & Expenses | $46.41M | $43.98M | $36.07M | $42.40M |
| Interest Income | $3.34M | $3.24M | $2.59M | $2.93M |
| Interest Expense | $2.56M | $2.52M | $2.53M | $2.57M |
| Depreciation & Amortization | $7.24M | $236000.00 | $239862.00 | $248139.00 |
| EBITDA | -$39.16M | -$40.40M | -$34.78M | -$33.16M |
| EBITDA Ratio | $0.00 | $0.00 | $0.00 | -$5.10 |
| Operating Income | -$46.41M | -$43.98M | -$36.07M | -$35.48M |
| Operating Income Ratio | $0.00 | $0.00 | $0.00 | -$5.13 |
| Other Income/Expenses (Net) | $4.45M | $869000.00 | -$1.48M | -$515000.00 |
| Income Before Tax | -$41.96M | -$43.11M | -$37.54M | -$36.003M |
| Income Before Tax Ratio | $0.00 | $0.00 | $0.00 | -$5.21 |
| Income Tax Expense | $608000.00 | $705000.00 | $480725.00 | $1.15M |
| Net Income | -$42.57M | -$43.82M | -$38.02M | -$37.16M |
| Net Income Ratio | $0.00 | $0.00 | $0.00 | -$5.38 |
| EPS | -$0.37 | -$0.40 | -$0.38 | -$0.38 |
| Diluted EPS | -$0.37 | -$0.40 | -$0.38 | -$0.38 |
| Weighted Avg Shares Outstanding | $116.25M | $109.49M | $99.89M | $97.92M |
| Weighted Avg Shares Outstanding (Diluted) | $116.25M | $109.49M | $99.89M | $97.92M |
Financial performance has remained strong, with revenue growing from $6.91M in Q4 2023 to $0.00 in Q3 2024. Gross profit continued to perform well, with margins at N/A in the latest quarter. Operating income reached -$46.41M in Q3 2024, holding a steady N/A margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$39.16M. Net income rose to -$42.57M, keeping EPS at -$0.37. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan